HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsuzaki, Y. Articles by Koga, Y. Search for Related Content PubMed PubMed Citation Articles by Matsuzaki, Y. Articles by Koga, Y.

Ann Thorac Surg 1995;59:127-131
© 1995 The Society of Thoracic Surgeons

Intrapleural Perfusion Hyperthermo-Chemotherapy for Malignant Pleural Dissemination and Effusion

Second Department of Surgery, Miyazaki Medical College, Miyazaki, Japan

Accepted for publication July 13, 1994.

Taking advantage of the antitumor effect of hyperthermia, we administered intrapleural perfusion hyperthermo-chemotherapy for the treatment of malignant pleural seeding or pleural effusion. This consists of irrigating the pleural space for 2 hours with 43°C saline solution containing cis-platinum using specially devised extracorporeal circuits. From January 1988 through December 1993, we performed this technique in 12 patients with malignant disseminated lesions stemming from lung cancer who also underwent surgical resection of the primary lesions and in 7 patients with malignant pleural effusions who did not undergo thoracotomy or surgical resection. There were no serious clinical complications associated with this procedure. The pharmacokinetics showed that a high concentration of cis-platinum (more than 17.6 µg/mL in the free form) was retained in the pleural cavity during perfusion. After this therapy, the cancer cells showed marked degeneration with fibrosis in the pleural wall. The pleural effusion was well controlled in 100% of the patients. The median survival time in the 12 patients with pleural disseminated lesions who were treated with intrapleural perfusion hyperthermo-chemotherapy was 20 months. On the other hand, the median survival time in 7 patients with similar lesions who did not receive IPHC was only 6 months. Intrapleural perfusion hyperthermo-chemotherapy seems to have considerable value as an adjuvant therapy for patients with pleural dissemination who have had their primary lesions removed.

This article has been cited by other articles:

				E. de Bree, S. van Ruth, C. E. Schotborgh, P. Baas, and F. A. N. Zoetmulder Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin Ann. Surg. Oncol., October 1, 2007; 14(10): 3019 - 3026. [Abstract] [Full Text] [PDF]

				W. G. Richards, L. Zellos, R. Bueno, M. T. Jaklitsch, P. A. Janne, L. R. Chirieac, B. Y. Yeap, R. J. Dekkers, P. M. Hartigan, L. Capalbo, et al. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma J. Clin. Oncol., April 1, 2006; 24(10): 1561 - 1567. [Abstract] [Full Text] [PDF]

				Y. Matsuzaki, M. Edagawa, T. Shimizu, M. Hara, M. Tomita, T. Ayabe, and T. Onitsuka Intrapleural Hyperthermic Perfusion With Chemotherapy Increases Apoptosis in Malignant Pleuritis Ann. Thorac. Surg., November 1, 2004; 78(5): 1769 - 1772. [Abstract] [Full Text] [PDF]

				N. Shigemura, A. Akashi, T. Nakagiri, K. Hazama, M. Ohta, and H. Matsuda Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread Ann. Thorac. Surg., March 1, 2004; 77(3): 1016 - 1021. [Abstract] [Full Text] [PDF]

				N. Shigemura, A. Akashi, M. Ohta, and H. Matsuda Combined surgery of intrapleural perfusion hyperthermic chemotherapy and panpleuropneumonectomy for lung cancer with advanced pleural spread: a pilot study Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 671 - 675. [Abstract] [Full Text] [PDF]

				T. Osaki, K. Sugio, T. Hanagiri, M. Takenoyama, T. Yamashita, M. Sugaya, M. Yasuda, and K. Yasumoto Survival and prognostic factors of surgically resected T4 non-small cell lung cancer Ann. Thorac. Surg., June 1, 2003; 75(6): 1745 - 1751. [Abstract] [Full Text] [PDF]

				R. A Vertrees, A. Leeth, M. Girouard, J. D Roach, and J. B Zwischenberger Whole-body hyperthermia: a review of theory, design and application Perfusion, July 1, 2002; 17(4): 279 - 290. [Abstract] [PDF]

				E. de Bree, S. van Ruth, P. Baas, E. J. Th. Rutgers, N. van Zandwijk, A. J. Witkamp, and F. A. N. Zoetmulder Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy in Patients With Malignant Pleural Mesothelioma or Pleural Metastases of Thymoma Chest, February 1, 2002; 121(2): 480 - 487. [Abstract] [Full Text] [PDF]

				G. B. Ratto, D. Civalleri, M. Esposito, E. Spessa, A. Alloisio, F. D. Cian, and M. O. Vannozzi PLEURAL SPACE PERFUSION WITH CISPLATIN IN THE MULTIMODALITY TREATMENT OF MALIGNANT MESOTHELIOMA: A FEASIBILITY AND PHARMACOKINETIC STUDY J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 759 - 765. [Abstract] [Full Text] [PDF]

				I. Birdi, I. Regragui, M. B. Izzat, A. J. Bryan, and G. D. Angelini INFLUENCE OF NORMOTHERMIC SYSTEMIC PERFUSION DURING CORONARY ARTERY BYPASS OPERATIONS: A RANDOMIZED PROSPECTIVE STUDY J. Thorac. Cardiovasc. Surg., September 1, 1997; 114(3): 475 - 481. [Abstract] [Full Text]

				R. J. Downey, V. F. Trastek, and R. P. Clay Right pneumonectomy syndrome: Surgical correction with expandable implants J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 953 - 955. [Full Text]